Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Genmab (GMAB – Research Report), AbbVie (ABBV – Research Report) and Immunome (IMNM – Research Report).
Genmab (GMAB)
Leerink Partners analyst Jonathan Chang maintained a Hold rating on Genmab on April 3 and set a price target of $29.00. The company’s shares closed last Friday at $29.76.
According to TipRanks.com, Chang is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genmab with a $39.75 average price target.
See the top stocks recommended by analysts >>
AbbVie (ABBV)
In a report issued on April 5, David Risinger from Leerink Partners maintained a Hold rating on AbbVie, with a price target of $173.00. The company’s shares closed last Friday at $170.00.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $180.86.
Immunome (IMNM)
In a report issued on April 3, Andrew Berens from Leerink Partners maintained a Buy rating on Immunome, with a price target of $38.00. The company’s shares closed last Friday at $20.26.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunome with a $35.50 average price target, representing a 76.0% upside. In a report issued on March 28, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMAB:
- Genmab price target lowered to DKK 2,750 from DKK 2,800 at UBS
- M&A News: Genmab (NASDAQ:GMAB) Is Acquiring ProfoundBio for $1.8B
- Genmab Expands Oncology Reach with ProfoundBio Buyout
- Genmab acquires ProfoundBio for $1.8B in cash
- Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
